Alpha Teknova (TKNO) Stock Price, News & Analysis

Company Overview

Alpha Teknova, Inc. (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations. Alpha Teknova also provides process development and scale-up manufacturing services for clients seeking tailored reagents or contract production, enabling seamless transition from bench-scale research to commercial-scale manufacturing.

Headquartered in Hollister, California, Alpha Teknova serves a global customer base with sales and distribution channels across North America, Europe and Asia. Founded to streamline and enhance life science research, the company’s management team combines deep expertise in research, product development and commercial operations, positioning Alpha Teknova to address evolving needs in the biotechnology and pharmaceutical sectors.

Key Stats

• Today's Range: $4.20 to $4.36
• 50-Day Range: $4.11 to $5.28
• 52-Week Range: $4.00 to $10.37
• Volume: 61,268 shs
• Average Volume: 352,400 shs
• Market Capitalization: $233.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Strong Buy

Alpha Teknova Stock Analysis - MarketRank™

Alpha Teknova scored higher than 62% of companies evaluated by MarketBeat, and ranked 450th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Alpha Teknova has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Alpha Teknova has a consensus price target of $10.00, representing about 129.4% upside from its current price of $4.36.

Amount of Analyst Coverage

Alpha Teknova has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alpha Teknova are expected to grow in the coming year, from ($0.58) to ($0.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpha Teknova is -10.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpha Teknova is -10.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpha Teknova has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

26.11% of the float of Alpha Teknova has been sold short.

Short Interest Ratio / Days to Cover

Alpha Teknova has a short interest ratio ("days to cover") of 9.3.

Change versus previous month

Short interest in Alpha Teknova has recently decreased by 6.76%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpha Teknova does not currently pay a dividend.

Dividend Growth

Alpha Teknova does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

26.11% of the float of Alpha Teknova has been sold short.

Short Interest Ratio / Days to Cover

Alpha Teknova has a short interest ratio ("days to cover") of 9.3.

Change versus previous month

Short interest in Alpha Teknova has recently decreased by 6.76%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Alpha Teknova has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Alpha Teknova this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for TKNO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alpha Teknova insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,480.00 in company stock.

Percentage Held by Insiders

12.50% of the stock of Alpha Teknova is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 13.81% of the stock of Alpha Teknova is held by institutions.

TKNO Stock Analysis - Frequently Asked Questions

How have TKNO shares performed this year?

Alpha Teknova's stock was trading at $8.35 on January 1st, 2025. Since then, TKNO shares have decreased by 47.8% and is now trading at $4.36.

How were Alpha Teknova's earnings last quarter?

Alpha Teknova, Inc. (NASDAQ:TKNO) posted its earnings results on Thursday, August, 7th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. The firm had revenue of $10.29 million for the quarter, compared to analysts' expectations of $9.90 million. Alpha Teknova had a negative net margin of 55.24% and a negative trailing twelve-month return on equity of 26.51%.
Read the conference call transcript.

When did Alpha Teknova IPO?

Alpha Teknova (TKNO) raised $90 million in an IPO on Friday, June 25th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share.

Who are Alpha Teknova's major shareholders?

Top institutional shareholders of Alpha Teknova include Balyasny Asset Management L.P. (1.87%), Geode Capital Management LLC (0.56%), Bank of America Corp DE (0.43%) and Massar Capital Management LP (0.37%). Insiders that own company stock include Telegraph Hill Partners Iv, L, Ted Davis, J Matthew Mackowski, Stephen Gunstream, Matthew Lowell, Damon Terrill, Lisa Hood, Ken Gelhaus and Martha J Demski.
View institutional ownership trends.

How do I buy shares of Alpha Teknova?

Shares of TKNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alpha Teknova own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alpha Teknova investors own include Myomo (MYO), Cassava Sciences (SAVA), Heron Therapeutics (HRTX), Taboola.com (TBLA), Ultralife (ULBI), NVIDIA (NVDA) and Sensus Healthcare (SRTS).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/05/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TKNO
• CIK: 1850902
• Web: www.teknova.com
• Phone: 831-637-1100
• Fax: N/A
• Employees: 240
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Alpha Teknova: $10.00
• High Price Target: $12.00
• Low Price Target: $8.00
• Potential Upside/Downside: +135.8%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.75 million
• Net Margins: -55.24%
• Pretax Margin: -55.25%
• Return on Equity: -26.51%
• Return on Assets: -18.40%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 5.87
• Quick Ratio: 4.70

Sales & Book Value

• Annual Sales: $37.74 million
• Price / Sales: 6.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.55 per share
• Price / Book: 2.74

Miscellaneous

• Outstanding Shares: 53,510,000
• Free Float: 46,826,000
• Market Cap: $226.88 million
• Optionable: Not Optionable
• Beta: 0.31